Why investors are chasing US biotechs with Chinese characteristics
Drugs developed in Asian nation are increasingly being used to seed US start-ups
Related reading
US weight-loss biotech’s $600mn fund raise signals China’s role in drug trials
Clinical studies can be finished faster and cheaper than in US and provide an earlier sign of a drug’s potential
UK biotech keeps selling itself to America
A shortage of late-stage capital pushes the biggest prizes into US hands
Chinese IPOs in US falter amid scrutiny of manipulation schemes
Regulators crack down after trading in ‘toxic’ small-cap stocks from China inflicted losses on US investors
Chinese drugmakers shift from copycats to global innovators
Reforms, faster development and lower costs have turbocharged growth
Prices for lab monkeys surge on China biotech boom
More drugs entering middle or late-stage development drive up demand
Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech
Global pharmaceutical companies are aggressively searching for new medicines in China